The impact of the COVID-19 pandemic on inflammatory diseases and patient care: a multicenter analysis

  • Neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated diseases (MOGAD) are demyelinating conditions that require full-time care.
  • The impact of the COVID-19 pandemic on care for patients living with such diseases was assessed. Most patients received excellent care with high satisfaction ratings of HCP services. A further 88% of patients indicated immunotherapy remained unaltered. The risk of SARS-CoV-2 was low to moderate in 64% of patients, whilst patients (96%) who acquired SARS-CoV-2 reported no serious adversities. Vaccination rates were 89%, with only 4 cases exhibiting first time or confirmed attacks of NMOSD/MOGAD within 2–9 days of vaccine administration.
  • Patient care and treatment remained uncompromised with no decline in quality of life throughout the pandemic.